Zacks: Analysts Anticipate Agilent Technologies, Inc. (A) Will Announce Quarterly Sales of $1.08 Billion
Wall Street analysts forecast that Agilent Technologies, Inc. (NYSE:A) will report sales of $1.08 billion for the current quarter, Zacks reports. Seven analysts have made estimates for Agilent Technologies’ earnings, with estimates ranging from $1.07 billion to $1.08 billion. Agilent Technologies posted sales of $1.04 billion during the same quarter last year, which would indicate a positive year over year growth rate of 3.8%. The company is scheduled to issue its next earnings report after the market closes on Tuesday, August 15th.
According to Zacks, analysts expect that Agilent Technologies will report full-year sales of $1.08 billion for the current year, with estimates ranging from $4.37 billion to $4.42 billion. For the next fiscal year, analysts forecast that the firm will report sales of $4.64 billion per share, with estimates ranging from $4.58 billion to $4.70 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Agilent Technologies.
Agilent Technologies (NYSE:A) last announced its earnings results on Monday, May 22nd. The medical research company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.10. The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.05 billion. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.44 EPS.
Several research analysts have issued reports on the stock. Wells Fargo & Company upgraded shares of Agilent Technologies from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $42.92 to $60.73 in a report on Wednesday, July 12th. BidaskClub upgraded shares of Agilent Technologies from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Robert W. Baird increased their target price on shares of Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a report on Monday, July 10th. Finally, Jefferies Group LLC increased their target price on shares of Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $60.12.
Shares of Agilent Technologies (NYSE A) traded down 1.64% during midday trading on Wednesday, hitting $59.55. 1,763,346 shares of the stock were exchanged. Agilent Technologies has a 12 month low of $42.92 and a 12 month high of $61.84. The stock has a market cap of $19.14 billion, a P/E ratio of 33.47 and a beta of 1.30. The firm has a 50 day moving average of $60.03 and a 200-day moving average of $54.38.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be given a $0.132 dividend. This represents a $0.53 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Thursday, June 29th. Agilent Technologies’s payout ratio is currently 29.78%.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 32,511 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $55.48, for a total transaction of $1,803,710.28. Following the completion of the transaction, the chief executive officer now directly owns 260,346 shares of the company’s stock, valued at approximately $14,443,996.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick Kaltenbach sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $56.50, for a total transaction of $282,500.00. The disclosure for this sale can be found here. Insiders sold a total of 150,119 shares of company stock valued at $8,823,719 over the last ninety days.
A number of institutional investors have recently bought and sold shares of A. Skandinaviska Enskilda Banken AB publ raised its position in Agilent Technologies by 5.7% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 64,834 shares of the medical research company’s stock worth $3,428,000 after buying an additional 3,489 shares in the last quarter. British Columbia Investment Management Corp raised its position in Agilent Technologies by 96.7% in the first quarter. British Columbia Investment Management Corp now owns 357,983 shares of the medical research company’s stock worth $18,927,000 after buying an additional 175,992 shares in the last quarter. Garde Capital Inc. raised its position in Agilent Technologies by 4.2% in the fourth quarter. Garde Capital Inc. now owns 13,341 shares of the medical research company’s stock worth $608,000 after buying an additional 539 shares in the last quarter. Wesbanco Bank Inc. acquired a new position in Agilent Technologies during the first quarter worth about $215,000. Finally, Creative Planning raised its position in Agilent Technologies by 6.3% in the first quarter. Creative Planning now owns 11,961 shares of the medical research company’s stock worth $632,000 after buying an additional 710 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.